ERK-mediated transcriptional activation of Dicer is involved in gemcitabine resistance of pancreatic cancer

Yen Hao Su, Tung Wei Hsu, Hsin An Chen, Chih Ming Su, Ming Te Huang, Ta Hsien Chuang, J. Leo Su, Chia Ling Hsieh, Ching Feng Chiu

研究成果: 雜誌貢獻文章同行評審


Gemcitabine has been a commonly used therapeutic agent for treatment of pancreatic cancer. In the clinic, a growing resistance to gemcitabine has been observed in patients with pancreatic cancer, and investigation of the underlying mechanism of gemcitabine resistance is urgently required. The microRNA (miRNA)-producing enzyme, Dicer, is crucial for the maturation of miRNAs, and is involved in clinical aggressiveness, poor prognosis, and survival outcomes in various cancers, however, the role of Dicer in acquired gemcitabine resistance of pancreatic cancer is still not clear. Here, we found that Dicer expression was significantly increased in gemcitabine-resistant PANC-1 (PANC-1/GEM) cells compared with parental PANC-1 cells and observed a high level of Dicer correlated with increased risk of pancreatic cancer. Suppression of Dicer obviously decreased gemcitabine resistance in PANC-1/GEM cells; consistently, overexpression of Dicer in PANC-1 cells increased gemcitabine resistance. Moreover, we identified that transcriptional factor Sp1 targeted the promoter region of Dicer and found ERK/Sp1 signaling regulated Dicer expression in PANC-1/GEM cells, as well as positively correlated with pancreatic cancer progression and suggest that targeting the ERK/Sp1/Dicer pathway has potential therapeutic value for pancreatic cancer with acquired resistance to gemcitabine.

期刊Journal of Cellular Physiology
出版狀態接受/付印 - 2020

ASJC Scopus subject areas

  • Physiology
  • Clinical Biochemistry
  • Cell Biology

指紋 深入研究「ERK-mediated transcriptional activation of Dicer is involved in gemcitabine resistance of pancreatic cancer」主題。共同形成了獨特的指紋。